Novavax is also evaluating a COVID-19-influenza combination (CIC) vaccine candidate in a phase I/II study. The CIC vaccine combines NVX-CoV2373, its authorized protein-based COVID vaccine, and its investigational influenza vaccine in a single formulation. In October, Novavax announced top-line data from this study which demonstrated the CIC vaccine was feasible and immunogenic. The immune responses were comparable to the standalone influenza vaccine candidate and standalone NVX-CoV2373 formulations. Novavax expects to begin a confirmatory phase II study evaluating this vaccine by this year’s end.
Así que, en pocas palabras, Novavax tiene una vacuna segura que se adapta a las nuevas variantes, según el Dr. Glenn, tiene evidencia para prevenir la transmisión y es muy duradera.La vacuna de ARNm debilita su sistema inmunológico, el agotamiento de las células T, disminuye rápidamente, causa efectos secundarios intensos, prolonga el aclaramiento del virus, entra en la circulación sistémica y, además de eso, confunde al sistema inmunitario mediante la impresión. La última parte es la más aterradora de todas para mí. Significa que cualquier futura vacuna específica de ARNm que presenten, el cuerpo solo puede escupir los viejos anticuerpos.(Copiado de Yahoo Finance)
FDA authorizes Novavax’s Covid shots as mix-and-match booster to Pfizer or Modernahttps://www.cnbc.com/2022/10/19/fda-authorizes-novavaxs-covid-shots-as-mix-and-match-booster-to-pfizer-or-moderna.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022https://ir.novavax.com/2022-10-10-Novavax-to-Share-New-Data-from-Growing-Vaccine-Portfolio-at-World-Vaccine-Congress-Europe-2022Switzerland’s Federal Office of Public Health Recommends Novavax Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Olderhttps://ir.novavax.com/Switzerlands-Federal-Office-of-Public-Health-Recommends-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-as-a-Booster-in-Adults-Aged-18-and-OlderNovavax and SK bioscience File a Post Approval Change Application in South Korea for Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Olderhttps://ir.novavax.com/Novavax-and-SK-bioscience-File-a-Post-Approval-Change-Application-in-South-Korea-for-Nuvaxovid-TM-COVID-19-Vaccine-as-a-Booster-in-Adults-Aged-18-and-Older!!Viajeros al trennn!!